Literature DB >> 1389721

Atrial myxoma: tumour or trauma?

J Nolan1, P J Carder, P Bloomfield.   

Abstract

A mass lesion developed in the right atrium at the site of a trans-septal puncture after percutaneous balloon dilatation of the mitral valve in a man aged 74. The lesion had the pathological appearance of an atrial myxoma and seemed to have developed after trauma to the intra-atrial septum. This case suggests that at least some atrial myxomas are reactive rather than neoplastic in origin.

Entities:  

Mesh:

Year:  1992        PMID: 1389721      PMCID: PMC1024864          DOI: 10.1136/hrt.67.5.406

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  5 in total

1.  The development of cardiac myxomas and papillary endocardial lesions from mural thrombus.

Authors:  W R Salyer; D L Page; G M Hutchins
Journal:  Am Heart J       Date:  1975-01       Impact factor: 4.749

2.  The malignant potentiality of left atrial myxoma.

Authors:  R C Read; H J White; M L Murphy; D Williams; C N Sun; W H Flanagan
Journal:  J Thorac Cardiovasc Surg       Date:  1974-12       Impact factor: 5.209

3.  Chromosomally abnormal clones and nonrandom telomeric translocations in cardiac myxomas.

Authors:  G W Dewald; R J Dahl; J L Spurbeck; J A Carney; H Gordon
Journal:  Mayo Clin Proc       Date:  1987-07       Impact factor: 7.616

4.  Metastasizing atrial myxoma.

Authors:  I S Seo; T F Warner; R A Colyer; R F Winkler
Journal:  Am J Surg Pathol       Date:  1980-08       Impact factor: 6.394

5.  Glandular cardiac myxomas. Histologic, immunohistochemical, and ultrastructural evidence of epithelial differentiation.

Authors:  B I Goldman; C Frydman; N Harpaz; S F Ryan; D Loiterman
Journal:  Cancer       Date:  1987-05-15       Impact factor: 6.860

  5 in total
  1 in total

1.  Herpes simplex virus type 1 infection associated with atrial myxoma.

Authors:  Yanwen Li; Zhigang Pan; Yuan Ji; Mary Sheppard; Donald J Jeffries; Leonard C Archard; Hongyi Zhang
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.